| Title |
Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed GlioblastomaPhase Ib Trial for Glioblastoma
|
|---|---|
| Published in |
Clinical Cancer Research, January 2021
|
| DOI | 10.1158/1078-0432.ccr-20-3805 |
| Pubmed ID | |
| Authors |
David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosniak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, D. Craig Hooper |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 55% |
| United Kingdom | 1 | 9% |
| Italy | 1 | 9% |
| Unknown | 3 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
| Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 10% |
| Student > Doctoral Student | 3 | 8% |
| Other | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Student > Ph. D. Student | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 19 | 48% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 18% |
| Biochemistry, Genetics and Molecular Biology | 5 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Agricultural and Biological Sciences | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 5 | 13% |
| Unknown | 19 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 102. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2023.
All research outputs
#394,526
of 24,643,522 outputs
Outputs from Clinical Cancer Research
#198
of 13,069 outputs
Outputs of similar age
#11,713
of 516,797 outputs
Outputs of similar age from Clinical Cancer Research
#15
of 366 outputs
Altmetric has tracked 24,643,522 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,069 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 516,797 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 366 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.